US92332V1070 - Common Stock
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company...
Results from this trial are expected in 2025...
SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on...
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company...
VTYX stock results show that Ventyx Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson’s disease are both expected to initiate...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice ...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on...
VTYX stock results show that Ventyx Biosciences beat analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ventyx Biosciences (NASDAQ:VTYX) just reported results for the first quarter of...
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on...
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i)...
WHY: NEW YORK, NY - (NewMediaWire) - April 30, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”), of the important April 30, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
WHY: NEW YORK, NY - (NewMediaWire) - April 29, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”), of the important April 30, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i)...
NEW YORK, NY - (NewMediaWire) - April 28, 2024 - WHY: New York, N.Y., April 28, 2024. Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”), of the important April 30, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX)...
NEW YORK, NY - (NewMediaWire) - April 27, 2024 - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”), of the important April 30, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
WHY: NEW YORK, NY - (NewMediaWire) - April 26, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”), of the important April 30, 2024 lead plaintiff deadline.
WHY: NEW YORK, NY - (NewMediaWire) - April 26, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”), of the important April 30, 2024 lead plaintiff deadline.